

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the Month of December 2018**

**Commission File Number: 001-38547**

---

**Autolus Therapeutics plc**  
(Translation of registrant's name into English)

---

**Forest House  
58 Wood Lane  
White City  
London W12 7RZ  
United Kingdom**  
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F      ☐ Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

---

---

---

**Other Events*****Change in Fiscal Year***

On December 19, 2018, the board of directors of Autolus Therapeutics plc, or the Company, approved a change in the Company's fiscal year end from September 30 to December 31. The Company will file a transition report on Form 20-F to cover the transition period from October 1, 2018 to December 31, 2018.

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

### **Autolus Therapeutics plc**

Date: December 20, 2018

By: /s/ Christian Itin

Name Christian Itin, Ph.D.

Title Chief Executive Officer